ÜbersichtsarbeitOpen Access
Perioperative pancreatic ductal adenocarcinoma care in 2025: who needs neoadjuvant?—who needs radiation?
Gland Surgery · 2026-07 · 15 (7) · 203-203
DOI: 10.21037/gs-2026-0177 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Gland Surgery, 2026-07. Verfasst von Runan Sheng und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Qinghai University, Xining, China. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
FOLFIRINOXPancreatic ductal adenocarcinoma (PDAC)borderline resectablemolecular biomarkersneoadjuvant therapy
Autor:innen und Institutionen
- School of Pharmacy, Qinghai University, Xining, China.
- Department of Pathophysiology, Qinghai University Medical College, Xining, China.
- Department of Hepatobiliary Diseases, Qinghai Tibetan Hospital, Xining, China.
Zitieren
APA
Sheng, R., Wu, Q., & Lan, K. (2026). Perioperative pancreatic ductal adenocarcinoma care in 2025: who needs neoadjuvant?—who needs radiation?. Gland Surgery, 15(7), 203-203. https://doi.org/10.21037/gs-2026-0177
Vancouver
Sheng R, Wu Q, Lan K. Perioperative pancreatic ductal adenocarcinoma care in 2025: who needs neoadjuvant?—who needs radiation?. Gland Surgery. 2026;15(7):203-203. doi:10.21037/gs-2026-0177
BibTeX
@article{Sheng2026,
author = {Sheng, Runan and Wu, Qiong and Lan, Kejia},
title = {Perioperative pancreatic ductal adenocarcinoma care in 2025: who needs neoadjuvant?—who needs radiation?},
journal = {Gland Surgery},
year = {2026},
volume = {15},
number = {7},
pages = {203--203},
doi = {10.21037/gs-2026-0177}
}
EUVIMED